Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease

NCT07384897 | Recruiting

• 1 other identifier: IMMUNOPOUMON2
• Study Type: interventional
• Target: 425
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation. Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment. The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.

Conditions

Lung Cancer (Diagnosis); Sarcoidosis; Chronic Obstructive Pulmonary Disease; Immunotherapy Resistance; Immune Dysregulation

Keywords

lung cancer; Non-Small Cell Lung Cancer; Sarcoidosis; Chronic Obstructive Pulmonary Disease; COPD; Immune Cells; Tumor Microenvironment; Immune Dysregulation; Immunotherapy; Immunotherapy Resistance; Immune Profiling; Myeloid Cells; Neutrophils; Dendritic Cells; Inflammation; Chronic Inflammation; Immune suppression; Emergency myelopoiesis

Outcome Measures

Primary Outcomes (1)

• Progression free survival

  median Progression free survival

  Throughout the entire study, approximately during 7 years

Study Arms (6)

Patients with precancerous lung lesions

OTHER

Patients with precancerous lung lesions under clinical monitoring

Other: Peripheral Blood Collection for Immune Profiling

Lung cancer

ACTIVE COMPARATOR

Patients with a diagnosis of lung cancer (all stages)

Other: Peripheral Blood Collection for Immune Profiling

Sarcoidosis and COPD

OTHER

Patients with chronic inflammatory lung diseases

Other: Peripheral Blood Collection for Immune Profiling

Control group

OTHER

Control group of volunteers without known lung disease

Other: Peripheral Blood Collection for Immune Profiling

chronic granulomatous disease

OTHER

Children and adolescents weighing ≥10 kg with chronic granulomatous disease

Other: Peripheral Blood Collection for Immune Profiling

Adults undergoing orthopedic surgery following hip or femur fracture

OTHER

Bone Marrow of Adults undergoing orthopedic surgery following hip or femur fracture

Other: Peripheral Blood Collection for Immune Profiling

Interventions

Peripheral Blood Collection for Immune Profiling OTHER

Participants provide biological samples for immune profiling and translational research. Samples include peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue or rlymph node, bone marrow. No experimental treatments are given. Collected samples are analyzed to characterize immune cell populations and their functional and molecular features, with the aim of studying immune mechanisms involved in lung cancer, sarcoidosis, and COPD, as well as factors associated with disease progression and treatment response. All medical care and treatment decisions remain independent of study participation.

Adults undergoing orthopedic surgery following hip or femur fracture; Control group; Lung cancer; Patients with precancerous lung lesions; Sarcoidosis and COPD; chronic granulomatous disease

Eligibility Criteria

• Age: Up to 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of lung cancer
• Presence of precancerous lung lesions
• Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment
• Control group: individuals without known lung disease
• Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
• Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected

You may not qualify if:

• Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent)
• Refusal or inability to provide informed consent (or assent, when applicable)
• Chronic inflammatory lung disease currently treated with immunosuppressive therapy

Sponsors & Collaborators

• Université Catholique de Louvain: lead

Study Sites (1)

Cliniques universitaires saint Luc

Brussels, 1200, Belgium

RECRUITING

Related Publications (5)

• Desai A, Prasad V. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 Oct;36(10):3202-3204. doi: 10.1007/s11606-021-06806-5. Epub 2021 Apr 26. No abstract available.

  PMID: 33904047 RESULT

• Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535.

  PMID: 31050774 RESULT

• Delhez N, Aboubakar Nana F, Houbion C, Bayard A, Bruger A, Vanhaver C, Brandau S, van der Bruggen P, Hirsch T. Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation. Methods Cell Biol. 2025;191:151-196. doi: 10.1016/bs.mcb.2024.10.010. Epub 2024 Nov 25.

  PMID: 39824555 RESULT

• Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21.

  PMID: 29785656 RESULT

• Vanhaver C, Aboubakar Nana F, Delhez N, Luyckx M, Hirsch T, Bayard A, Houbion C, Dauguet N, Brochier A, van der Bruggen P, Bruger AM. Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. Life Sci Alliance. 2023 Nov 6;7(1):e202302332. doi: 10.26508/lsa.202302332. Print 2024 Jan.

  PMID: 37931958 RESULT

MeSH Terms

Conditions

Lung Neoplasms; Disease; Sarcoidosis; Pulmonary Disease, Chronic Obstructive; Carcinoma, Non-Small-Cell Lung; Inflammation

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases; Lung Diseases, Obstructive; Chronic Disease; Disease Attributes; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Officials

• Frank Aboubakar Nana, MD; PhD

  Cliniques universistaires saint Luc

  STUDY DIRECTOR

Central Study Contacts

Frank Aboubakar Nana, MD; PhD

CONTACT

0032 2 764 85 19; frank.aboubakar@saintluc.uclouvain.be

Kim Henquin, Study nurse

CONTACT

0032 2 764 42 26; kim.henquin@saintluc.uclouvain.be

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a translational, non-interventional study evaluating immune cell populations in patients with lung cancer, sarcoidosis, and COPD. Participants receive only standard clinical care; no experimental treatments are given. Biological samples (primarily blood and when available, tumor, bone morrow samples collected for clinical reasons) and associated clinical data are analyzed to investigate immune mechanisms related to tumor progression, chronic lung inflammation, and response or resistance to therapy. The study is exploratory and comparative across diseases. All treatment decisions are made independently by the treating physicians and are not influenced by study participation.

Study Record Dates

• First Submitted: January 26, 2026
• First Posted: February 3, 2026
• Study Start: February 17, 2025
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): February 17, 2032
• Last Updated: February 3, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)